Prediction of response to primary chemotherapy for operable breast cancer

European Journal of Cancer

Volumn 35, Issue 4, 1999, Pages 574-579

  Colleoni, M ^a   Orvieto, E ^a   Nole, F ^a   Orlando, L ^a   Minchella, I ^a   Viale, G ^a   Peruzzotti, G ^a   Robertson, C ^a   Noberasco, C ^a   Galimberti, V ^a   Sacchini, V ^a   Veronesi, P ^a   Zurrida, S ^a   Orecchia, R ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cyclophosphamide; Doxorubicin; Predictive features; Preoperative chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY KI 67; NAVELBINE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE C ERB; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, NUCLEAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; NUCLEAR PROTEINS; PREOPERATIVE CARE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0033118545     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00005-2     Document Type: Article

References (36)

1. Bonadonna G., Valagussa P. Primary chemotherapy in operable breast cancer. Semin. Oncol. 4:1996;464-474.
2. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res. 52:1992;2127-2137.
3. Hortobagyi G.N., Ames F.C., Buzdar A.U., et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer. 62:1988;2507-2516.
4. Bonadonna G., Valagussa P., Zucali R., Salvadori B. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J. Clin. 45:1995;227-243.
5. Mauriac L., Durand M., Avril A. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: results of a randomized trial in a single centre. Ann. Oncol. 2:1991;347-354.
6. Bonadonna G., Veronesi U., Brambilla C. Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters or more. J. Natl. Cancer Inst. 2:1990;1539-1545.
7. Veronesi U., Salvadori B., Luini A. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur. J. Cancer. 31A:1995;1574-1579.
8. Fisher B., Briant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16:1998;2672-2685.
9. Scholl S.M., Fourquet A., Asselain B., et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial. Eur. J. Cancer. 30A:1994;645-652.
10. Powles T.J., Hickish T.F., Makris A., et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J. Clin. Oncol. 13:1995;547-552.
11. Schabel Jr F.M. Concepts for systemic treatment of micrometastases. Cancer. 35:1975;15-24.
12. Smith I.E., Walsh G., Jones A., et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J. Clin. Oncol. 13:1995;424-429.
13. Chollet Ph., Charrier S., Brain E., et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur. J. Cancer. 33:1997;862-866.
14. Makris A., Powles T.J., Dowsett M., et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 3:1997;593-600.
15. Koechli O.R., Schaer G.N., Seifert B., et al. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet. 451:1994;1647-1648.
16. MacGrogan G., Mauriac L., Durand M., et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST. Br. J. Cancer. 74:1996;1458-1465.
17. Gottardi G., Scanzi F., Zurrida S., et al. Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer. Breast. 208:1993;33-36.
18. Billgren A., Rutqvist L.E., Skoog L., et al. Changes of proliferating fraction during neoadjuvant chemotherapy of primary breast cancer as a predictor of objective response. Breast Cancer Res. Treat. 32:1994;63.
19. Ellis P., Smith I., Ashley S., et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 16:1998;107-114.
20. Nolè F., De Braud F., Aapro M., et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with low subjective toxic burden. Ann. Oncol. 8:1997;865-870.
21. Bosari A., Lee A.K.C., Viale G., et al. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long term follow up. Virchows. Archiv. A Pathol. Anat. 421:1992;291-295.
22. Pegram M.D., Lipton A., Hayes D.F., et al. Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185 Her/Neu monoclonal antibody plus cisplatin in patients with HER/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16:1998;2659-2671.
23. Tannock I. Cell Kinetics and chemotherapy: a critical review. Cancer Treat. Rep. 62:1978;117-133.
24. Drewinko B., Patchen M., Yang L.Y., et al. Differential killing efficacy of twenty antitumor drugs on proliferating and non proliferating human tumor cells. Cancer Res. 41:1981;2328-2333.
25. Lowe S.W., Earl Ruley H., Jaks T., Housman D.E. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-964.
26. McIlwrath A.J., Vasey P.A., Ross G.M., et al. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild type p53 for radiosensitivity. Cancer Res. 54:1994;3718-3722.
27. Buttita F., Marchetti A., Gadducci A., et al. p53 alterations are predictive of chemoresistance and agressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer. 75:1997;230-235.
28. Rush V., Klimstra D., Venkatraman E., et al. Aberrant p53 expression predicts clinical resistance to cisplatin based chemotherapy in locally advanced non small cell lung cancer. Cancer Res. 555:1995;5038-5042.
29. Smith M.L., Chen T.I., Zhan Q., et al. Interaction of the p-53 regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 266:1994;1376-1380.
30. Bradford C.R., Zhu S., Wolf G.T., et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation therapy in advanced laryngeal cancer. Otoryngol. Head Neck Surg. 113:1995;408-412.
31. Allred D.C., Clark G.M., Fuqua S.A.W., et al. Overexpression of p53 in node positive breast cancer. Proc. Am. Soc. Clin. Oncol. 14:1995;103.
32. Marchetti A., Buttita F., Pellegrini S., et al. p53 mutations and histological types of invasive breast carcinoma. Cancer Res. 53:1993;4665-4669.
33. Muss H.B., Thor A.D., Berry D., et al. c-erbB-2 expression and reponse to adjuvant therapy in women with node positive breast cancer. N. Engl. J. Med. 330:1994;1260-1266.
34. Gusterson B.A., Gelber R.D., Goldhirsch A., et al. Prognostic importance for c-erbB-2 expression in breast cancer. J. Clin. Oncol. 10:1992;1049-1056.
35. Kaufman M., Klinga K., Runnembaum M., et al. In vitro adriamycin sensitivity test and hormonal receptors in primary breast cancer. Cancer. 47:1980;2797-2800.
36. Jain V., Landry M., Levine E.A. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast cancer. Am. Surg. 62:1996;162-165.